Raffaele Colombo: A record 77 new ADCs entered clinical development in 2024
Raffaele Colombo, Associate Director of Medicinal Chemistry at Zymeworks Inc., shared a post on X about a paper by him and colleagues published in Cancer Discovery:
“A record 77 new ADCs entered clinical development in 2024 (including those accepted but not yet started).
Payload class was clearly dominated by topo1i with 55 ADCs.
Greater diversity was observed in antibody targets, featuring novel TAAs and several bispecific ADCs.”
“The Journey of Antibody–Drug Conjugates: Lessons Learned from 40 Years of Development “
Authors: Raffaele Colombo, Paolo Tarantino, Jamie Rich, Patricia LoRusso, Elisabeth de Vries.
More posts featuring Raffaele Colombo.
Raffaele Colombo, a leading figure in the pharmaceutical industry is the Associate Director of Medicinal Chemistry at Zymeworks Inc.. His leadership and scientific acumen drive the discovery and optimization of novel drug candidates and advancing the treatment landscape for various diseases.
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023